Salute e Benessere
Navamedic Q1 2025: Strong start of the year and well-positioned for future growth
"After investing in several strategic growth initiatives last year, we are pleased to see strong results already in the first quarter of 2025. The positive impact of the Nordic tender wins for our antibiotics portfolio has just begun to materialize. In addition, several products, including and from our Prescription Drugs (RX) segment, delivered strong performance in the quarter," said Kathrine Gamborg Andreassen , CEO of Navamedic.
"We are also pleased to announce the renewal of our agreement with TopRidge Pharma, securing the exclusive rights to market and sell for another eight years. Over the past few years, we have systematically expanded and matured our product portfolio while investing in initiatives to drive future growth. The strong start to 2025 confirms the progress we are making," she added.
During the first quarter, the (up 11.5 per cent YoY) and (up 15.2 per cent YoY) business areas delivered strong growth. had a steady development in the period (up 0.3 per cent YoY).
As part of the Prescription Drugs area, revenues of increased by 7.3 per cent YoY. During the quarter, the European Medicines Agency's Human Medicines Committee also announced its review of Mysimba®. It affirmed that the benefits continue to outweigh the risks for weight management in adults with obesity or overweight.
and performed well in the quarter and were up 54 per cent and 22 per cent, respectively. , the company's unique treatment for Parkinson's Disease, delivered sales growth of 13 per cent YoY. had a revenue decrease of 45 per cent due increased competition.
For the area, the two tender wins drove sales growth in the portfolio, which is up 32 per cent YoY, whilst the portfolio maintained steady sales.
The company's third business area, , delivered stable results. Revenues of were steady during Q1, whilst (up 49 per cent YoY) and (up 8 per cent YoY) experienced strong growth. saw a 9 per cent decrease in revenues, which is explained by a stock build-up in Q1 2024.
Operating results (EBIT) for the first quarter of 2025 amounted to NOK 9.1 million , compared to NOK 4.9 million in 2024. Operating costs ended at NOK 40.9 million , compared to NOK 38.3 million last year. Net financial items ended at negative NOK 11 million and profit before tax was negative NOK 1.8 million .
Navamedic continues to see strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company.
"We have had a strong start to 2025. We have several key hero products across our three business areas, many of which have the potential to succeed internationally. Part of our work moving forward will be to identify growth opportunities for these products to support future growth," Andreassen concluded.
Navamedic will present the results for the first quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo . It will be webcast at the following link:
https://navamedic.com/investors/financial-results/
Kathrine Gamborg Andreassen , CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/navamedic-asa/r/navamedic-q1-2025--strong-start-of-the-year-and-well-positioned-for-future-growth,c4143204
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/navamedic-q1-2025-strong-start-of-the-year-and-well-positioned-for-future-growth-302442213.html